Newer LAMA
Reading File
Finding Sources
Finding Sources
Searching PubMed
"long-acting muscarinic antagonist" LAMA COPD newer
Finding Sources
Searching PubMed
"glycopyrronium" OR "umeclidinium" OR "aclidinium" OR "revefenacin" COPD
Reading File
Reading File
Finding Sources
Finding Sources
Searching the Web
revefenacin nebulizer LAMA COPD 2024 2025 newer LAMA comparison
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information. Here is the full answer:
Newer LAMAs (Long-Acting Muscarinic Antagonists)
Mechanism of Action
LAMAs block muscarinic (M3) receptors on airway smooth muscle and mucus-secreting glands, inhibiting vagally mediated bronchoconstriction and mucus hypersecretion. The result is sustained bronchodilation and improved airflow. Dry mouth is the most common side effect, caused by M3 blockade in salivary glands. Caution is needed in narrow-angle glaucoma and prostatic hyperplasia.
The Newer LAMA Agents
The classical LAMA is ipratropium (short-acting, QID). The true LAMAs used in COPD management are listed below. Beyond tiotropium (the prototype), four newer agents are now in widespread use:
| Drug | Dosing | Device | Notes |
|---|---|---|---|
| Tiotropium (prototype) | Once daily | DPI (18 µg) or MDI (5 µg) | First major LAMA; "kinetically selective" - dissociates slowly from M3 vs M2 |
| Aclidinium bromide | Twice daily | DPI (400 µg) | Faster onset than tiotropium; BID dosing may suit some patients |
| Glycopyrronium (glycopyrrolate) | Twice daily | DPI (15.6 µg) | Available as monotherapy and in combination inhalers |
| Umeclidinium | Once daily | DPI (62.5 µg) | Very long duration; often combined with vilanterol (Anoro Ellipta) |
| Revefenacin | Once daily | Nebulizer only | Unique - the only once-daily nebulized LAMA; for patients unable to use inhalers |
Sources: Harrison's Principles of Internal Medicine 22E (2025); Goldman-Cecil Medicine; Lippincott Illustrated Reviews Pharmacology
Key Differences Among Newer LAMAs
1. Aclidinium (e.g., Tudorza Pressair)
- BID dosing distinguishes it from most other LAMAs
- Onset of action is faster than tiotropium, which may provide more immediate symptom control
- Available as a dry powder inhaler
2. Glycopyrronium / Glycopyrrolate (e.g., Seebri Breezhaler, Lonhala Magnair)
- Quaternary ammonium compound - minimal systemic absorption, favorable tolerability
- Available in dry powder inhaler (BID) and nebulized form (glycopyrrolate - Lonhala Magnair, once-daily nebulizer)
- Key component of combination inhalers (Utibron = glycopyrronium + indacaterol; Bevespi = glycopyrrolate + formoterol)
3. Umeclidinium (e.g., Incruse Ellipta)
- Once daily - very long receptor dissociation half-life
- Highly selective for M3
- Major use in triple therapy: Fluticasone furoate/Umeclidinium/Vilanterol (Trelegy Ellipta) - one of the two main single-inhaler triple therapies (SITT) for COPD
4. Revefenacin (Yupelri)
- Unique delivery - the only LAMA administered exclusively by nebulizer (once daily)
- Designed for patients with severe COPD who cannot generate sufficient inspiratory flow for DPI use, or who prefer/require nebulized therapy
- Newer FDA approval (2018); useful in patients on home nebulizers
Role in COPD Management
Per current guidelines (GOLD/Harrison's), LAMAs are the preferred first-line long-acting bronchodilator for most COPD patient groups:
| COPD Group | Recommended Treatment |
|---|---|
| A (low risk, fewer symptoms) | SABA, SAMA, LABA, or LAMA |
| B (low risk, more symptoms) | LABA or LAMA |
| C (high risk, fewer symptoms) | LAMA preferred |
| D (high risk, more symptoms) | LAMA ± LABA ± ICS |
LAMAs reduce symptoms and exacerbation frequency. LAMAs are preferred over LABAs as monotherapy for high-risk patients (Group C/D).
LAMA + LABA combinations (dual bronchodilation) are more effective than either alone when single-agent control is inadequate. Current fixed-dose dual combinations include:
- Umeclidinium/Vilanterol (Anoro Ellipta)
- Glycopyrronium/Indacaterol (Utibron)
- Tiotropium/Olodaterol (Stiolto Respimat)
- Aclidinium/Formoterol (Duaklir)
Triple therapy (ICS + LABA + LAMA) in a single inhaler reduces mortality in selected COPD patients. The two main SITTs are:
- Fluticasone furoate/Umeclidinium/Vilanterol (Trelegy Ellipta)
- Budesonide/Glycopyrrolate/Formoterol fumarate (Breztri Aerosphere)
Recent comparative evidence (BMJ 2024, PMID 39797646) and matching-adjusted indirect comparisons suggest both triple-therapy combinations have similar overall effectiveness, though mortality outcomes remain an area of active research.
Side Effects (Class-wide)
- Dry mouth (most common, M3-mediated)
- Constipation
- Urinary retention (caution in BPH)
- Worsening narrow-angle glaucoma (avoid inhaler spray in eyes)
- Paradoxical bronchospasm (rare)
All are minor compared to benefit in COPD. - Harrison's Principles of Internal Medicine 22E (2025, McGraw Hill), p. COPD section
This is a shared conversation. Sign in to Orris to start your own chat.